InvestorsHub Logo
Followers 6
Posts 1400
Boards Moderated 0
Alias Born 08/24/2014

Re: Titan V post# 41935

Wednesday, 11/15/2017 10:18:21 PM

Wednesday, November 15, 2017 10:18:21 PM

Post# of 48316
I think you are absolutely right about that Titan. No other reason to have brought Dan O'Connor on board if not to stir up interest from other companies. 2 million share stock options awarded to Dan is good incentive to get this done too.

I think any major interest from other big pharma will have Merck shaking in their boots and force a buyout of Oncosec at a premium valuation.

Merck has alot of reasons for an Oncosec takeover in that they could go after non-responders in any indication Keytruda is approved for. So far TNBC and Head and Neck cancer seem like the obvious choices to start with. NSCLC would be big.